Copenhagen-based SNIPR Biome, a BioTech company focused on microbial CRISPR-medicine, has closed a €35 million Series B round to further CRISPR-based therapies for cystic fibrosis airway infections, tackle antibiotic resistance, and support clinical trials of SNIPR001 for blood cancer patients.
The funding round included new investors the Cystic Fibrosis Foundation and the German Federal Agency for Breakthrough Innovation (SPRIN-D), along with existing investors Lundbeckfonden BioCapital, North-East Family Office, and Wellington Partners.
“This financing is a pivotal milestone for SNIPR BIOME as we move forward with the clinical development of SNIPR001 to prevent bloodstream infections and expand our pipeline targeting critical pathogens,” said Christian Grøndahl, CEO and Co-founder. “This support highlights the importance of tackling antimicrobial resistance and infectious diseases.”
Founded in 2011, SNIPR Biome is a clinical-stage company pioneering CRISPR-medicine. They leverage CRISPR-Cas technology to treat and prevent diseases by precisely targeting bacteria or modifying genes.
The technology provides selective, rapid eradication of target bacteria and removes antibiotic resistance genes, preserving the patient’s microbial community. SNIPR technology also creates CRISPR-medicine to produce therapeutics selectively in the gastrointestinal tract, targeting bacteria via programmable, genome-specific approaches.
SNIPR Biome was the first to orally dose humans with CRISPR therapeutics and received US and European patents for CRISPR targeting of microbiomes.
SNIPR001 is in a Phase 1b (NCT06938867) study at eight US cancer centers, co-funded by CARB-X. Their technology is used in partnerships with CARB-X, Gates Foundation, Cystic Fibrosis Foundation, IPATH, SPRIN-D, and MD Anderson Cancer Center.
This funding will develop a CRISPR-Cas therapy targeting airway infections in cystic fibrosis patients, and advance CRISPR-based interventions to eliminate antibiotic resistance genes in various bacterial species and environments.
The funding also supports SNIPR001’s clinical development in hematologic cancer patients, including the ongoing phase 1b trial.